These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37954899)

  • 1. Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial.
    Aubron C; Chapalain X; Bailey M; Board J; Buhr H; Cartwright B; Dennis M; Hodgson C; Forrest P; McIlroy D; Murphy D; Murray L; Pellegrino V; Pilcher D; Sheldrake J; Tran H; Vallance S; Cooper DJ; McQuilten Z
    Crit Care Explor; 2023 Nov; 5(11):e0999. PubMed ID: 37954899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial.
    Aubron C; McQuilten Z; Bailey M; Board J; Buhr H; Cartwright B; Dennis M; Hodgson C; Forrest P; McIlroy D; Murphy D; Murray L; Pellegrino V; Pilcher D; Sheldrake J; Tran H; Vallance S; Cooper DJ;
    Crit Care Med; 2019 Jul; 47(7):e563-e571. PubMed ID: 31033512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein-induced activated partial thromboplastin time prolongation in heparinized samples is attenuated by elevated factor VIII.
    Kostousov V; Devaraj S; Bruzdoski K; Hensch L; Hui SK; Teruya J
    Int J Lab Hematol; 2021 Feb; 43(1):139-142. PubMed ID: 32812381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-factor Xa vs aPTT for heparin monitoring in extracorporeal membrane oxygenation.
    Vo T; Bello A; Ragan M; Flanagan J; Johnson D
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S77-S83. PubMed ID: 36478046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support.
    Arnouk S; Altshuler D; Lewis TC; Merchan C; Smith DE; Toy B; Zakhary B; Papadopoulos J
    ASAIO J; 2020 Mar; 66(3):300-306. PubMed ID: 31045921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordance among assays for monitoring? Anticoagulation during extracorporeal life support.
    Scott EJ; Rotar E; Dahl JJ; Beller JP; Money DT; Chancellor WZ; Mehaffey JH; Morisette M; Yarboro LT; Teman NR
    Perfusion; 2023 Nov; 38(8):1714-1721. PubMed ID: 36167522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
    Kostousov V; Nguyen K; Hundalani SG; Teruya J
    Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study.
    Saito T; Hayakawa M; Kumano O; Honma Y; Murashita M; Kato J; Fukui S; Takahashi M; Takahashi Y; Tsuchida T; Mizugaki A; Takauji S; Hayamizu M; Yoshida T; Katabami K; Wada T; Maekawa K
    J Intensive Care; 2023 Nov; 11(1):54. PubMed ID: 37974289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation.
    Buckley MS; Benanti GE; Meckel J; Tekle LA; Gilbert B; Puebla Neira D; McNierney DA; Korkames G; Yerondopoulos M; Park A; O'Hea JA; MacLaren R
    Pharmacotherapy; 2023 Mar; 43(3):196-204. PubMed ID: 36759323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation.
    Hohlfelder B; Kelly D; Hoang M; Anger KE; Sylvester KW; Kaufman RM; Connors JM
    Am J Ther; 2022 Jul; 29(4):e385-e393. PubMed ID: 31833874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.
    Kulig CE; Schomer KJ; Black HB; Dager WE
    ASAIO J; 2021 Apr; 67(4):411-415. PubMed ID: 33769995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.
    Moussa MD; Soquet J; Lamer A; Labreuche J; Gantois G; Dupont A; Abou-Arab O; Rousse N; Liu V; Brandt C; Foulon V; Leroy G; Schurtz G; Jeanpierre E; Duhamel A; Susen S; Vincentelli A; Robin E
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34067573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anticoagulation monitoring strategies for adults supported on extracorporeal membrane oxygenation: A systematic review.
    Sun J; Ma Y; Su W; Miao H; Guo Z; Chen Q; Zhang Y; Ma X; Chen S; Ding R
    Heart Lung; 2023; 61():72-83. PubMed ID: 37167901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls.
    Kessel AD; Kline M; Zinger M; McLaughlin D; Silver P; Sweberg TM
    J Intensive Care Med; 2017 Jan; 32(1):59-67. PubMed ID: 26319579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.